Quisinostat [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.

====== Quisinostat ======


Quisinostat (USAN; development code JNJ-26481585) is an experimental drug candidate for the treatment of cancer. It is a "second generation" [[histone deacetylase inhibitor]] with antineoplastic activity. It is highly potent against class I and II HDACs.

It was developed by Janssen Pharmaceuticals and licensed to NewVac LLC.

Preclinical studies show that quisinostat amplifies HDAC-repressed expression of E-cadherin, leading to a reversal of epithelial to mesenchymal transition in tumor cells. Results of a phase I trials in patients with multiple myeloma in combination with bortezomib and dexamethasone were published in 2016.
----


Data provide strong evidence that [[Quisinostat]] or other class I HDAC inhibitors might be therapeutically useful for patients with [[SHH medulloblastoma]] including those resistant to [[Smoothened]] (SMO) inhibition
((Pak E, MacKenzie EL, Zhao X, Pazyra-Murphy MF, Park PMC, Wu L, Shaw DL,
Addleson EC, Cayer SS, Lopez BG, Agar NYR, Rubin LL, Qi J, Merk DJ, Segal RA. A
large-scale drug screen identifies selective inhibitors of class I HDACs as a
potential therapeutic option for SHH medulloblastoma. Neuro Oncol. 2019 May 16.
pii: noz089. doi: 10.1093/neuonc/noz089. [Epub ahead of print] PubMed PMID:
31111916.
)).